FDA maintained its position that CBD in any ingestible form is subject to the drug preclusion language in the federal Food Drug and Cosmetic Act via refusal letters posted regarding New Dietary Ingredient Notifications (NDIN) filed by Charlotte’s Web and
Continue Reading FDA Rejects CBD New Dietary Ingredient Notifications: Four Practical Takeaways
CBD and Hemp Legal and Regulatory Roundup – July 30, 2021
Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news:
CBD
CBA calls for clear federal regulations relation to OTC sales of CBD products
In a letter to the acting commissioner of the FDA, the Consumer Brands
Continue Reading CBD and Hemp Legal and Regulatory Roundup – July 30, 2021
CBD and Hemp Legal and Regulatory Roundup – July 23, 2021
Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news:
CBD
Iowa Court of Appeals upholds state’s view of CBD as controlled substance
The Iowa Appeals Court sided with the Marion Civil Service Commission, saying Sarah Hyatt
Continue Reading CBD and Hemp Legal and Regulatory Roundup – July 23, 2021
FDA Enforcement: There’s Nothing Inactive About CBD and “FDA Registered” Is Misleading
On Monday, FDA announced two warning letters issued to makers of topical CBD products labeled as OTC drugs. Amidst a backdrop of facility inspections that revealed significant good manufacturing compliance concerns, the most important takeaways in this round of CBD
Continue Reading FDA Enforcement: There’s Nothing Inactive About CBD and “FDA Registered” Is Misleading
CBD and Hemp Legal and Regulatory Roundup
Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news:
CBD
FDA CBD regulations put on pause as new administration moves in
The removal of an FDA review of a CBD enforcement policy was anticipated as the
Continue Reading CBD and Hemp Legal and Regulatory Roundup
Another Federal Court Halts False Advertising Case Pending FDA Review of CBD
On May 22, Central California District Court Judge Virginia A. Phillips granted CBD retailer CV Sciences, Inc.’s (CV Sciences) request to stay the case of Colette et al. v. CV Sciences Inc., Case No. 2:19-cv-10227 (C.D. Cal), until the
Continue Reading Another Federal Court Halts False Advertising Case Pending FDA Review of CBD
FDA and FTC Joint Warning Letters Target Amazon Affiliates Making False COVID-19 Claims
Earlier this week, federal regulators continued their efforts to combat the spread of products featuring allegedly false and misleading claims that products can diagnose, treat, cure, or prevent COVID-19. In warning letters issued to CBD Gaze, Alternavita, Musthavemom.com
Continue Reading FDA and FTC Joint Warning Letters Target Amazon Affiliates Making False COVID-19 Claims
CBD Manufacturer Not Immune From FDA Enforcement For COVID-19 Claims
In the midst of continued enforcement regarding coronavirus marketing, FDA sent a warning letter to NeuroXPF concerning advertising for its CBD products alleging that they can boost immune systems to help consumers avoid contracting the virus. Citing the need to
Continue Reading CBD Manufacturer Not Immune From FDA Enforcement For COVID-19 Claims
KDW COVID-19 Resource Center Provides Critical Business Guidance
As the novel coronavirus (COVID-19) has reached pandemic levels, companies of all sizes and in all industries face myriad impacts to business operations and the health and well-being of employees.
To help clients navigate these new challenges, including the unpredictability
Continue Reading KDW COVID-19 Resource Center Provides Critical Business Guidance
FDA Sends CBD Status Report to Congress; Market Clarity Remains Elusive
Earlier this week, FDA sent its status report regarding a potential CBD enforcement discretion policy to Congress. As we wrote here, FDA was required to issue the report per the Joint Explanatory Statement attached to the 2020 Ag Appropriations
Continue Reading FDA Sends CBD Status Report to Congress; Market Clarity Remains Elusive